Alpha 2.0
Login Register
» Articles » PMID: 32258341

Surveyed Dermatologists Are Less Likely to Curette Invasive Squamous Cell Carcinoma in Solid Organ Transplant Recipients

Overview
Journal Int J Womens Dermatol
Publisher Wolters Kluwer
Date 2020 Apr 8
PMID 32258341
Authors
Kathleen M Nemer
Tyler M Bauman
M Laurin Council
Eva A Hurst
Affiliations
Soon will be listed here.
Abstract

Background: The risk of squamous cell carcinoma (SCC) is increased in solid organ transplant recipients (OTRs), and preferential treatment modalities vary among clinicians.

Objectives: The purpose of this study was to survey dermatologists regarding practice patterns for electrodesiccation and curettage (EDC) of SCC in OTRs and nontransplant patients.

Methods: An 18-question survey was sent to dermatologist members of the International Transplant Skin Cancer Collaborative, Association of Professors of Dermatology, and American College of Mohs Surgery. Differences in EDC practice patterns for treatment of SCC in OTRs and nontransplant patients were evaluated.

Results: Dermatologists in this study ( = 227) were more likely to treat SCC with EDC in nontransplant patients (67.4%) than in OTRs (48.0%; P = .0003).Dermatologists who perform EDC in both groups ( = 108) were unlikely to use EDC on the H-zone of the face; they were more likely to EDC tumors on non-H-zone areas of the face and neck in nontransplant patients compared to OTRs ( = .0007). Dermatologists were more likely to use EDC over surgery in nontransplant patients compared to OTRs with the following demographics: dementia or psychiatric disease ( = .04), multiple medical comorbidities ( = .03), or anticoagulation medications ( = .02).

Conclusions: In OTRs with SCC, 48% of clinicians would consider EDC. The main factors that affect the decision to perform EDC include tumor location and patient comorbidities.

References
1.
Reschly M, Shenefelt P . Controversies in skin surgery: electrodessication and curettage versus excision for low-risk, small, well-differentiated squamous cell carcinomas. J Drugs Dermatol. 2010; 9(7):773-6. View
2.
Rowe D, Carroll R, Day Jr C . Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol. 1992; 26(6):976-90. DOI: 10.1016/0190-9622(92)70144-5. View
3.
Stasko T, Brown M, Carucci J, Euvrard S, Johnson T, Sengelmann R . Guidelines for the management of squamous cell carcinoma in organ transplant recipients. Dermatol Surg. 2004; 30(4 Pt 2):642-50. DOI: 10.1111/j.1524-4725.2004.30150.x. View
4.
Chockalingam R, Downing C, Tyring S . Cutaneous Squamous Cell Carcinomas in Organ Transplant Recipients. J Clin Med. 2015; 4(6):1229-39. PMC: 4484997. DOI: 10.3390/jcm4061229. View
5.
Carucci J, Martinez J, Zeitouni N, Christenson L, Coldiron B, Zweibel S . In-transit metastasis from primary cutaneous squamous cell carcinoma in organ transplant recipients and nonimmunosuppressed patients: clinical characteristics, management, and outcome in a series of 21 patients. Dermatol Surg. 2004; 30(4 Pt 2):651-5. DOI: 10.1111/j.1524-4725.2004.30151.x. View